Tag Archives: WACKER expands biotechnology services with new Contract Research Services platform for nucleic acid medicines

WACKER introduces end-to-end R&D and manufacturing support for emerging RNA and gene therapy technologies

(IN BRIEF) WACKER has launched a new Contract Research Services platform designed to support biotech and biopharma companies developing nucleic acid-based medicines, including RNA therapies, plasmid DNA technologies and lipid nanoparticle formulations. Operating from the company’s Biotechnology Center in Munich, … Read the full press release